Virtuu Biologics (AgeTech UK) Biomed
Virttu has pioneered the development of oncolytic viruses for treating cancer. Although viruses naturally kill the cells they infect, weakened viruses have been used in medicine for centuries as vaccinations against the infectious diseases they cause. Scientists at Virttu have reprogrammed this ability in a common human virus so that it targets and kills only cancer cells (oncolysis), leaving normal cells unharmed. Additionally, the presence of the tumour-specific viral infection works as a vaccination triggering the patient’s own immune system to mount an anti-cancer response – a treatment known as oncolytic immunotherapy.
Technology:
AgeTech Companies
Industry:
UK AgeTech 2020
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership